4 news items
Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
STRO
13 May 24
to build upon our momentum and are well positioned on our goal to rapidly deliver precisely designed ADCs to patients in need
Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering
STRO
2 Apr 24
of preclinical and clinical trials, the Company's ability to fund development activities and achieve development goals, the Company's ability to protect
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
STRO
2 Apr 24
, the timing and results of preclinical and clinical trials, the Company's ability to fund development activities and achieve development goals
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones
STRO
25 Mar 24
goals, the Company's ability to protect intellectual property, the value of the Company's holdings of Vaxcyte common stock, and the Company's commercial
- Prev
- 1
- Next